<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04151615</url>
  </required_header>
  <id_info>
    <org_study_id>BR-BTZ-OS-401</org_study_id>
    <nct_id>NCT04151615</nct_id>
  </id_info>
  <brief_title>VMP Regimen - Safety, Efficacy, and Optimal Dose Finding Study for Patients With Multiple Myeloma</brief_title>
  <acronym>VISION</acronym>
  <official_title>A Multi-center,Open, Longitudinal, Observational Study to Evaluate the Treatment Effectiveness and Safety of the Bortezomib-melphalan-prednisolone Regimen in Treatment-naïve Patients With Multiple Myeloma, Ineligible for Hematopoietic Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boryung Pharmaceutical Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boryung Pharmaceutical Co., Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The 3-drug therapy of Bortezomib-Melphalan-Prednisolone (VMP) is a standard therapy that is
      commonly used currently in South Korea as a first-line treatment for treatment-naïve patients
      with multiple myeloma who are ineligible for hematopoietic transplantation. Despite the fact
      that VMP therapy is outstanding in terms of cost-effectiveness, treatment discontinuation
      rates due to adverse drug reactions is high. In addition, when considering that the
      percentage of elderly patients aged 70 years or above in the target patient group is 20% or
      above, there have been attempts to devise a plan that can decrease side effects while
      maintaining effectiveness. For example, there have been previous reported cases of overseas
      applications of modified VMP therapies with reduced doses, but they have applied various
      combinations in terms of the total cycles, administration intervals, doses, etc. This study
      was planned to evaluate the overall safety and efficacy of VMP therapy by following up on the
      actual VMP therapies applied in domestic clinics, patient characteristics, side effect
      occurrences, administration discontinuation rates, survival data, etc., as well as to collect
      exploratory data for a more effective study of modified VMP therapies.

      This study was planned to evaluate the overall safety and efficacy of VMP therapy by
      following up on the actual VMP therapies applied in domestic clinics, patient
      characteristics, side effect occurrences, administration discontinuation rates, survival
      data, etc., as well as to collect exploratory data for a more effective study of modified VMP
      therapies.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The data produced when subjects visit the hospital for treatment are collected in case report
      forms. The follow-up time specified in the following refer to the data collection time. That
      is, a subject's visit schedule is freely determined by the investigator based on the medical
      condition of the subject regardless of the follow-up time specified in this protocol, but
      data that are determined necessary in relation to the study among the data produced during
      the study period may be collected in CRFs.

      In regard to various tests for monitoring of treatment effects including laboratory tests,
      the corresponding tests are not performed separately for this clinical study, and only those
      items with existing test results are collected. The following data are collected in CRFs
      during the study period.

        -  Demographic information of subjects

        -  Information on multiple myeloma disease (diagnosis date, diagnosis criteria and related
           test results, disease stage [ISS and revised ISS], number of osseous lesions)

        -  Intercurrent diseases

        -  Height and body weight

        -  ECOG PS

        -  IMWG Frailty score

        -  Laboratory results

        -  Radiologic results

        -  Bone marrow examination results

        -  Supportive therapy administered for symptoms related to multiple myeloma (drug / surgery
           / radiotherapy)

        -  Detailed information of administered VMP therapy

        -  Maintenance therapy / VMP replacement therapy

        -  Clinical response

        -  Survival

        -  Adverse drug reactions related to VMP therapy

        -  Serious adverse events/adverse drug reactions
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 15, 2018</start_date>
  <completion_date type="Anticipated">January 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>PFS (progression-free survival)</measure>
    <time_frame>18 Month after VMP therapy administration</time_frame>
    <description>the survival rate curve of PFS and the median, as well as the 95% confidence interval for this are presented. An event is 'confirmation of progressive disease (PD)' or 'death,' and others are processed as censored at the later time point between the final follow-up time point and the time point of final clinical response evaluation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ORR (Overall Response Rate)</measure>
    <time_frame>18 Month after VMP therapy administration</time_frame>
    <description>The frequency and percentage of subjects who reach CR, VGPR, and PR even once after VMP therapy administration are calculated, and the 95% CI for the percentage is presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CR (Complete Response)</measure>
    <time_frame>18 Month after VMP therapy administration</time_frame>
    <description>The frequency and percentage of subjects who reach CR even once after VMP therapy administration are calculated, and the 95% CI for the percentage is presented</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Response (TTR)</measure>
    <time_frame>18 Month after VMP therapy administration</time_frame>
    <description>time to first response and time to best response; here, response must be higher than partial response (PR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Progression (TTP)</measure>
    <time_frame>18 Month after VMP therapy administration</time_frame>
    <description>'confirmation of progressive disease,' and others are processed as censored at the final follow-up time point or the time point of final clinical response evaluation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Next Treatment (TTNT)</measure>
    <time_frame>18 Month after VMP therapy administration</time_frame>
    <description>'administration of VMP replacement therapy (regardless of VMP therapy termination),' and others are processed as censored at the final follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS (Overall Survival)</measure>
    <time_frame>18 Month after VMP therapy administration</time_frame>
    <description>'death,' and others are processed as censored at the final time point with confirmed survival.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of IMWG frailty scores at Cycle 5 and Cycle 9</measure>
    <time_frame>18 Month after VMP therapy administration</time_frame>
    <description>The frequency and percentage of IMWG frailty scores (Fit: 0 points, Intermediate-fitness: 1 point, Frail: ≥2 points) per time point are presented. The mean, standard deviation, median, minimum value, and maximum value for the variance of IMWG frailty scores at VMP therapy Cycle 5 and Cycle 9 compared to the baseline are summarized with descriptive statistics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prognosis prediction factors</measure>
    <time_frame>18 Month after VMP therapy administration</time_frame>
    <description>Prognosis variables: PFS/TTR/TTP/OS
Potential prediction factors: Age / ISS stage / revised ISS stage / number of osseous lesions / IMWG frailty score at baseline (0 points, 1 point, ≥2 points) / VMP administration pattern</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">203</enrollment>
  <condition>Treatment-naïve Patients With Multiple Myeloma Who Are Ineligible for Hematopoietic Transplantation</condition>
  <arm_group>
    <arm_group_label>Patients</arm_group_label>
    <description>Treatment-naïve patients with multiple myeloma who are ineligible for hematopoietic transplantation</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Treatment-naïve patients with multiple myeloma who are ineligible for hematopoietic
        transplantation
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who provide written consent on the informed consent form for use of personal
             information after listening to an explanation regarding the purpose, method, etc., of
             this clinical study

          -  Adult males and females aged 19 years or above

          -  Patients without previous experience of treatment for multiple myeloma who have been
             evaluated as ineligible for hematopoietic transplantation

          -  Patients scheduled to receive the 3-drug combination (VMP therapy) treatment

          -  Patients with expected survival period of 6 months or more

          -  Patients evaluated as having performance status score (ECOG PS) ≤2 (score of 0, 1, 2)

          -  Patients who have received the following tests within 6 months prior to enrollment

               -  Beta2-microglobulin

               -  Serum albumin

               -  Serum LDH

               -  Patients with confirmed del (17), t (4;14), t (14;16) by hybridization FISH test

        Exclusion Criteria:

          -  Patients who have been newly diagnosed with other primary cancers within the last 5
             years that can affect the treatment or prognosis of multiple myeloma

          -  Pregnant women and breast-feeding women

          -  Patients who are currently participating in other clinical studies (drug or medical
             device clinical studies) or planning to participate in other clinical studies during
             the study participation period

          -  Patients who are determined ineligible to participate in the study by other judgments
             of the investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hyo Jae Kim</last_name>
    <role>Study Director</role>
    <affiliation>Boryung Pharmaceutical Co., Ltd</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hyo Jae Kim</last_name>
    <phone>+82-2-708-8203</phone>
    <email>igniter@boryung.co.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Soonchunhyang University Bucheon hospital</name>
      <address>
        <city>Bucheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Se Hyung Kim, MD</last_name>
    </contact>
    <investigator>
      <last_name>Se Hyung Kim, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Inje university Haeundae Paik Hospital</name>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sung Nam Lim, MD, Ph.D.</last_name>
    </contact>
    <investigator>
      <last_name>Sung Nam Lim, MD, Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kosin University Gospel hospital</name>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Da Jung Kim, MD.</last_name>
    </contact>
    <investigator>
      <last_name>Da Jung Kim, MD.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pusan national University Hospital</name>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ho Jin Shin, MD, Ph.D</last_name>
    </contact>
    <investigator>
      <last_name>Ho Jin Shin, MD, Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chungbuk national university Hospital</name>
      <address>
        <city>Chungbuk</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ji Hyun Kwon, MD</last_name>
    </contact>
    <investigator>
      <last_name>Ji Hyun Kwon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dankook University Hospital</name>
      <address>
        <city>Chungnam</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Do Hyoung Lim, MD</last_name>
    </contact>
    <investigator>
      <last_name>Do Hyoung Lim, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Keimyung University Hospital(Dongsan Medical Center)</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Young Rok Do, MD, Ph.D.</last_name>
    </contact>
    <investigator>
      <last_name>Young Rok Do, MD, Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yeungnam University Medical Center</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Min Kyoung Kim, MD, Ph.D.</last_name>
    </contact>
    <investigator>
      <last_name>Min Kyoung Kim, MD, Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chungnam National University Hospital</name>
      <address>
        <city>Daejeon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yoon Seok Choi, MD</last_name>
    </contact>
    <investigator>
      <last_name>Yoon Seok Choi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Cancer Center</name>
      <address>
        <city>Goyang</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hyeon-Seok Eom, MD, Ph.D.</last_name>
    </contact>
    <investigator>
      <last_name>Hyeon-Seok Eom, MD, Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gyeongsang National University Changwon Hospital</name>
      <address>
        <city>Gyeongsang</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hoon-Gu Kim, MD</last_name>
    </contact>
    <investigator>
      <last_name>Hoon-Gu Kim, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chonnam National University Hwasun Hospital</name>
      <address>
        <city>Hwasun</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Je Jung Lee, MD, Ph.D.</last_name>
    </contact>
    <investigator>
      <last_name>Je Jung Lee, MD, Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gachon University Gil Medical Center</name>
      <address>
        <city>Incheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jae Hoon Lee, MD, Ph.D</last_name>
    </contact>
    <investigator>
      <last_name>Jae Hoon Lee, MD, Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chung-Ang University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jun Ho Yi, M.D.</last_name>
    </contact>
    <investigator>
      <last_name>Jun Ho Yi, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kangbuk Samsung Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Suk-Joong Oh, MD, Ph.D.</last_name>
    </contact>
    <investigator>
      <last_name>Suk-Joong Oh, MD, Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Korea University Anam Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Byung Soo Kim, MD, Ph.D.</last_name>
    </contact>
    <investigator>
      <last_name>Byung Soo Kim, MD, Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kihyun Kim, MD</last_name>
    </contact>
    <investigator>
      <last_name>Kihyun Kim, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jin Seok Kim, MD, Ph.D.</last_name>
    </contact>
    <investigator>
      <last_name>Jin Seok Kim, MD, Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Soonchunhyang University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jong-Ho Won, MD, Ph.D.</last_name>
    </contact>
    <investigator>
      <last_name>Jong-Ho Won, MD, Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Catholic University of Korea, Seoul ST. Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ajou University Medical Center</name>
      <address>
        <city>Suwon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joon Seong Park, MD</last_name>
    </contact>
    <investigator>
      <last_name>Joon Seong Park, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ulsan University hospital</name>
      <address>
        <city>Ulsan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jae Cheoul Cho, MD, Ph.D.</last_name>
    </contact>
    <investigator>
      <last_name>Jae Cheoul Cho, MD, Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wonju Severance Christian Hospital</name>
      <address>
        <city>Wonju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shin Young Hyun, MD, Ph.D.</last_name>
    </contact>
    <investigator>
      <last_name>Shin Young Hyun, MD, Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>November 1, 2019</study_first_submitted>
  <study_first_submitted_qc>November 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 5, 2019</study_first_posted>
  <last_update_submitted>November 1, 2019</last_update_submitted>
  <last_update_submitted_qc>November 1, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Multiple Myeloma</keyword>
  <keyword>Treatment-naïve patients</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

